Pulmonary hypertension: Classification and diagnostic algorithm

Italian Heart Journal

Volumn 6, Issue 10, 2005, Pages 834-839

  Manes, Alessandra ^a   Campana, Carlo ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Diagnosis; Hemodynamics; Prognosis; Pulmonary hypertension

Indexed keywords

ALGORITHM; CLASSIFICATION; DIAGNOSTIC IMAGING; ELECTROCARDIOGRAPHY; HOSPITALIZATION; HUMAN; LUNG FUNCTION TEST; METHODOLOGY; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW;

ALGORITHMS; DIAGNOSTIC IMAGING; ELECTROCARDIOGRAPHY; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX;

EID: 33644677558     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hatano S, Strasser T. Primary pulmonary hypertension. Geneva: World Health Organization, 1975.
2. Simonneau G, Galiè N, Rubin L, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (Suppl S): 5S-12S.
3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-9.
4. Galiè N, Manes A, Uguccioni L, et al. Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest 1998; 114 (Suppl): 184S-194S.
5. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43 (Suppl S): 25S-32S.
6. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (Suppl S): 13S-24S.
7. Humbert M, Chaouat A, Bertocchi M, et al. ItinerAIR-HTAP: a French national prospective registry of pulmonary arterial hypertension. (abstr) Am J Respir Crit Care Med 2004: 169: A169.
8. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001; 104: 2797-802.
9. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 461-6.
10. Hinderliter AL, Willis PW 4th, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation 1997; 95: 1479-86.
11. Galiè N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 1380-6.
12. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, for the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
13. Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23: 637-48.
14. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161 (Part 1): 487-92.
15. Galiè N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002; 20: 1037-49.
16. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
17. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-70.
18. Galiè N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995; 75: 55A-62A.
19. Sitbon O, Humbert M, Ioos V, et al. Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension? (abstr) Am J Respir Crit Care Med 2003; 167: A440.
20. Galiè N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (Suppl S): 81S-88S.